Literature DB >> 18812504

A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.

Christopher D Sibley1, Michael D Parkins, Harvey R Rabin, Kangmin Duan, Jens C Norgaard, Michael G Surette.   

Abstract

Lung disease is the leading cause of morbidity and mortality in cystic fibrosis (CF) patients. A modest number of bacterial pathogens have been correlated with pulmonary function decline; however, microbiological and molecular evidence suggests that CF airway infection is polymicrobial. To obtain a more complete assessment of the microbial community composition and dynamics, we undertook a longitudinal study by using culture-independent and microbiological approaches. In the process, we demonstrated that within complex and dynamic communities, the Streptococcus milleri group (SMG) can establish chronic pulmonary infections and at the onset of 39% of acute pulmonary exacerbations, SMG is the numerically dominant pathogen. We report the comprehensive polymicrobial community dynamics of a CF lung infection in a clinically relevant context. If a given organism, such as Pseudomonas aeruginosa, becomes resistant to antibiotic therapy, an alternative treatment avenue may mediate the desired clinical response by effectively managing the composition of the microbial community.

Entities:  

Mesh:

Year:  2008        PMID: 18812504      PMCID: PMC2567494          DOI: 10.1073/pnas.0804326105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  The importance of recognising Streptococcus milleri as a cause of orbital cellulitis.

Authors:  J L Ball; R M Malhotra; P Leong; A S Bacon
Journal:  Eye (Lond)       Date:  2000-10       Impact factor: 3.775

2.  Association between Streptococcus milleri and abscess formation after appendicitis.

Authors:  R H Hardwick; A Taylor; M H Thompson; E Jones; A M Roe
Journal:  Ann R Coll Surg Engl       Date:  2000-01       Impact factor: 1.891

3.  Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms.

Authors:  E L Ong; M E Ellis; A K Webb; K R Neal; M Dodd; E O Caul; S Burgess
Journal:  Thorax       Date:  1989-09       Impact factor: 9.139

4.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

Authors:  Eric E Smith; Danielle G Buckley; Zaining Wu; Channakhone Saenphimmachak; Lucas R Hoffman; David A D'Argenio; Samuel I Miller; Bonnie W Ramsey; David P Speert; Samuel M Moskowitz; Jane L Burns; Rajinder Kaul; Maynard V Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-10       Impact factor: 11.205

Review 5.  The Streptococcus milleri group--an unrecognized cause of disease in cystic fibrosis: a case series and literature review.

Authors:  Michael D Parkins; Christopher D Sibley; Michael G Surette; Harvey R Rabin
Journal:  Pediatr Pulmonol       Date:  2008-05

6.  Streptococci and aerococci associated with systemic infection in man.

Authors:  M T Parker; L C Ball
Journal:  J Med Microbiol       Date:  1976-08       Impact factor: 2.472

7.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus (the Streptococcus milleri group): association with different body sites and clinical infections.

Authors:  R A Whiley; D Beighton; T G Winstanley; H Y Fraser; J M Hardie
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

9.  Trends in antimicrobial susceptibility of the Streptococcus milleri group.

Authors:  Natsuo Yamamoto; Toru Kubota; Masato Tohyama; Shuzo Kanamori; Takashi Shinzato; Futoshi Higa; Masao Tateyama; Atsushi Saito
Journal:  J Infect Chemother       Date:  2002-06       Impact factor: 2.211

10.  Degradation and utilisation of chondroitin sulphate by Streptococcus intermedius.

Authors:  H Shain; K A Homer; D Beighton
Journal:  J Med Microbiol       Date:  1996-05       Impact factor: 2.472

View more
  164 in total

Review 1.  Next-generation sequencing in the analysis of human microbiota: essential considerations for clinical application.

Authors:  Geraint B Rogers; Kenneth D Bruce
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

Review 2.  Role of the gut microbiota in defining human health.

Authors:  Kei E Fujimura; Nicole A Slusher; Michael D Cabana; Susan V Lynch
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

3.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

Review 4.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

Review 5.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

Review 6.  The role of the bacterial microbiome in lung disease.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

7.  Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model.

Authors:  Laura M Filkins; Jyoti A Graber; Daniel G Olson; Emily L Dolben; Lee R Lynd; Sabin Bhuju; George A O'Toole
Journal:  J Bacteriol       Date:  2015-04-27       Impact factor: 3.490

Review 8.  Pseudomonas aeruginosa biofilms in disease.

Authors:  Lawrence R Mulcahy; Vincent M Isabella; Kim Lewis
Journal:  Microb Ecol       Date:  2013-10-06       Impact factor: 4.552

9.  Characterization of Streptococcus milleri group isolates from expectorated sputum of adult patients with cystic fibrosis.

Authors:  Margot E Grinwis; Christopher D Sibley; Michael D Parkins; Christina S Eshaghurshan; Harvey R Rabin; Michael G Surette
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

10.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.